Kite, a Gilead Company (GILD), has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. The transaction is expected to reduce Gilead's GAAP and non-GAAP 2025 EPS by approximately $0.23-$0.25.
Interius is a clinical stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases in oncology, autoimmunity and beyond. Interius's team and operations will integrate into Kite's research team, creating a center of excellence in Philadelphia to accelerate the development of next-generation in vivo therapies.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.